|
1) Cooper KH. A means of assessing maximal oxygen intake. Correlation between field and treadmill testing. JAMA. 1968; 203: 201-4
|
|
|
|
2) McGavin CR, Gupta SP, McHardy GJ. Twelve-minute walking test for assessing disability in chronic bronchitis. Br Med J. 1976; 1: 822-3
|
|
|
|
|
|
3) Butland RJ, Pang J, Gross ER, et al. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed). 1982; 284: 1607-8
|
|
|
|
|
|
4) 厚生省特定疾患｢呼吸不全｣調査研究班. 呼吸不全—診断と治療のためのガイドライン. 東京: メディカルレビュー社; 1996. p. 16-23
|
|
|
|
|
|
5) 日本呼吸管理学会呼吸リハビリテーションガイドライン作成委員会, 日本呼吸器学会ガイドライン施行管理委員会, 日本理学療法士協会呼吸リハビリテーションガイドライン作成委員会. 呼吸リハビリテーションマニュアル—運動療法. 東京: 照林社; 2003. p. 76-9
|
|
|
|
|
|
6) Criner GJ, Cordova FC, Furukawa S, et al. Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 160: 2018-27
|
|
|
|
|
|
7) Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000; 161: 487-92
|
|
|
|
|
|
8) Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000; 342: 1866-70
|
|
|
|
|
|
9) Kadikar A, Maurer J, Kesten S. The six-minute walk test: a guide to assessment for lung trans-plantation. J Heart Lung Transplant. 1997; 16: 313-9
|
|
|
|
|
|
10) Cahalin LP, Mathier MA, Semigran MJ, et al. The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest. 1996; 110: 325-32
|
|
|
|
|
|
11) ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS Statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166: 111-7
|
|
|
|
|
|
12) Sciurba F, Criner GJ, Lee SM, et al. Six-minute walk distance in chronic obstructive pulmonary disease: Reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med. 2003; 167: 1522-7
|
|
|
|
|
|
13) Bansal V, Hill K, Dolmage TE, et al. Modifying track layout from straight to circular has a modest effect on the 6-min walk distance. Chest. 2008; 133: 1155-60
|
|
|
|
|
|
14) de Torres JP, Pinto-Plata V, Ingenito E, et al. Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. Chest. 2002; 121: 1092-8
|
|
|
|
|
|
15) Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350: 1005-12
|
|
|
|
|
|
16) Casanova C, Cote C, Marin JM, et al. Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. Chest. 2008; 134: 746-52
|
|
|
|
|
|
17) Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003; 168: 1084-90
|
|
|
|
|
|
18) Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med. 2006; 174: 803-9
|
|
|
|
|
|
19) Lederer DJ, Arcasoy SM, Wilt JS, et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006; 174: 659-64
|
|
|
|
|
|
20) Azuma A, Nukiwa T, Tsuboi E, et al. Double blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171: 1040-7
|
|
|
|
|